GLEN

Adial CEO to Present at the Spring MicroCap Rodeo Conference on June 6th

Retrieved on: 
Mercoledì, Maggio 29, 2024
GLEN, Conference, Cryptocurrency

GLEN ALLEN, Va., May 29, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will be participating in the Spring MicroCap Rodeo Conference that will be held on Thursday, June 6, 2024 in New York City.

Key Points: 
  • GLEN ALLEN, Va., May 29, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will be participating in the Spring MicroCap Rodeo Conference that will be held on Thursday, June 6, 2024 in New York City.
  • Cary Claiborne, President and Chief Executive Officer of Adial, is scheduled to present at 2:00 p.m. Eastern Time on Thursday, June 6th.
  • The presentation will be webcast live and available at https://www.webcaster4.com/Webcast/Page/3045/50687 as well as on the Company’s investor relations section of the website at www.adial.com/events .
  • Management will also be hosting 1x1 meetings throughout the conference with approved investors.

Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Mercoledì, Maggio 15, 2024
Partnership, Patient, OUD, Patent, European Journal, Annals of Internal Medicine, Exercise, FDA, Opioid use disorder, Drug development, Chemistry, ALD, Liver transplantation, GLEN, Open access, Manuscript, Data analysis, Internal medicine, Research, G&A, Pharmaceutical industry

GLEN ALLEN, Va., May 15, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the first quarter of 2024.

Key Points: 
  • GLEN ALLEN, Va., May 15, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the first quarter of 2024.
  • Cary Claiborne, President and Chief Executive Officer of Adial, stated, “We are making steady progress as it relates to AD04.
  • To support our efforts, we formally hired Tony Goodman as our Chief Operating Officer during the quarter.
  • Cash and cash equivalents were $5.0 million as of March 31, 2024, compared to $2.8 million as of December 31, 2023.

Health-tech innovator Remidio achieves unprecedented scale in the US with its revolutionary retinal solutions

Retrieved on: 
Martedì, Maggio 7, 2024
FDA, AMD, University, Risk, AI, Diabetic retinopathy, GLEN, Paratriathlon, ISO, Eye, Nursing, Patient, Acquisition, Assistant, CE

This quarter, Remidio Inc. is excited to be placing its 1000th FOP-NM handheld fundus camera in the hands of US healthcare providers.

Key Points: 
  • This quarter, Remidio Inc. is excited to be placing its 1000th FOP-NM handheld fundus camera in the hands of US healthcare providers.
  • Since 2019, these devices have been supporting diabetic retinopathy screening activities of over 3,500 high volume healthcare providers in the US.
  • As our vision for using retinal imaging, viewing the "windows to our body", won't end with just eye diseases.
  • The portability, affordability, and ease of use of Remidio devices naturally fit into already existing clinical workflows, enabling this technology to quickly scale its impact."

HAMILTON BEACH BRANDS HOLDING COMPANY ANNOUNCES DATES OF ITS 2024 FIRST QUARTER EARNINGS RELEASE AND CONFERENCE CALL

Retrieved on: 
Giovedì, Maggio 2, 2024
GLEN

GLEN ALLEN, Va., May 2, 2024 /PRNewswire/ -- Hamilton Beach Brands Holding Company (NYSE: HBB) announced today that it will release its 2024 first quarter financial results and file its 10-Q for the quarter ended March 31, 2024, after the close of the market on Tuesday, May 7, 2024.

Key Points: 
  • GLEN ALLEN, Va., May 2, 2024 /PRNewswire/ -- Hamilton Beach Brands Holding Company (NYSE: HBB) announced today that it will release its 2024 first quarter financial results and file its 10-Q for the quarter ended March 31, 2024, after the close of the market on Tuesday, May 7, 2024.
  • The Company will host a conference call on Wednesday, May 8, 2024, to discuss its results.

The Inner Circle Acknowledges Aaron T. Scott, DHA, CNMT, NMAA, FSNMMI-TS as a Distinguished Professional

Retrieved on: 
Lunedì, Aprile 29, 2024
Health administration, Capella University, Professional, Nuclear medicine, DHA, Health, Publication, Spectrum, Teaching, Clark Atlanta University, Molecular biophysics, Health care, Johns Hopkins Hospital, GLEN, IRB, ACLS, Inner circle, BLS, Master, NMAA, Multimedia, Mediocre, Doctorate, Medical college, Nursing

GLEN BURNIE, Md., April 29, 2024 /PRNewswire/ -- Aaron T. Scott, DHA, CNMT, NMAA, FSNMMI-TS is being recognized by The Inner Circle as a Distinguished Professional for his work in healthcare.

Key Points: 
  • GLEN BURNIE, Md., April 29, 2024 /PRNewswire/ -- Aaron T. Scott, DHA, CNMT, NMAA, FSNMMI-TS is being recognized by The Inner Circle as a Distinguished Professional for his work in healthcare.
  • As Vice President of Clinical Operations, Aaron holds a pivotal role at the Advanced Molecular Imaging & Therapy in Glen Burnie, MD.
  • Aaron ensures that clinical operations knowledge is effectively integrated into various clinical development activities.
  • He has held leadership positions in professional organizations, received awards, and made significant contributions to the field through publications and educational speaking engagements.

Glen Burnie Bancorp Announces First Quarter 2024 Results

Retrieved on: 
Venerdì, Aprile 26, 2024
Sale, Small business, Federal Reserve, Treasury, FHLB, Risk, Bank holding company, Federal Reserve Bank, Federal, GLEN, Bank, Risk management, Tax, Income tax, 127th, Growth

GLEN BURNIE, Md., April 26, 2024 (GLOBE NEWSWIRE) -- Glen Burnie Bancorp (“Bancorp”) (NASDAQ: GLBZ), the bank holding company for The Bank of Glen Burnie (“Bank”), today reported results for the first quarter ended March 31, 2024.

Key Points: 
  • GLEN BURNIE, Md., April 26, 2024 (GLOBE NEWSWIRE) -- Glen Burnie Bancorp (“Bancorp”) (NASDAQ: GLBZ), the bank holding company for The Bank of Glen Burnie (“Bank”), today reported results for the first quarter ended March 31, 2024.
  • Bancorp, the oldest independent commercial bank in Anne Arundel County, will pay its 127th consecutive quarterly dividend on May 6, 2024.
  • For the quarter ended March 31, 2024, noninterest expense totaled $2.86 million, a decrease of $83,000 compared to $2.94 million for the quarter ended March 31, 2023.
  • Glen Burnie Bancorp is a bank holding company headquartered in Glen Burnie, Maryland.

Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office

Retrieved on: 
Lunedì, Aprile 22, 2024
Opioid use disorder, OUD, GLEN, Obesity, Addiction, Patent, Patient, Alcohol, Pharmaceutical industry

GLEN ALLEN, Va., April 22, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11957664 was issued April 16, 2024 by the United States Patent and Trademark Office.

Key Points: 
  • GLEN ALLEN, Va., April 22, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 11957664 was issued April 16, 2024 by the United States Patent and Trademark Office.
  • Cary Claiborne, CEO of Adial, commented, “We are proud to have secured this new patent, which covers important aspects of the combination of our proprietary genetic diagnostic and AD04 to treat AUD, OUD, and other drug dependencies.
  • Importantly, we have identified specific genotypes that have responded with clinically meaningful changes in drinking behavior compared to placebo in the AD04 post hoc analysis, which represents an addressable market of approximately $40 billion in the U.S. alone.
  • We believe our unique personalized approach can offer new hope to the millions affected by AUD, OUD and other addictive disorders such as obesity and gambling.”

Glen Burnie Bancorp Declares 1Q 2024 Dividend

Retrieved on: 
Venerdì, Aprile 12, 2024
News, Risk, Security (finance), GLEN, Bank, Anne Arundel County, Maryland

GLEN BURNIE, Md., April 12, 2024 (GLOBE NEWSWIRE) -- Glen Burnie Bancorp (NASDAQ: GLBZ), parent company of The Bank of Glen Burnie®, announced that its Board of Directors declared a regular dividend of ten cents ($0.10) per share of common stock at their meeting on April 11, 2024.

Key Points: 
  • GLEN BURNIE, Md., April 12, 2024 (GLOBE NEWSWIRE) -- Glen Burnie Bancorp (NASDAQ: GLBZ), parent company of The Bank of Glen Burnie®, announced that its Board of Directors declared a regular dividend of ten cents ($0.10) per share of common stock at their meeting on April 11, 2024.
  • The regular dividend is payable on May 6, 2024, to shareholders of record at the close of business on April 22, 2024.
  • Glen Burnie Bancorp, parent company to The Bank of Glen Burnie, currently maintains consolidated assets totaling $369.9 million at March 31, 2024.
  • Founded in 1949, The Bank of Glen Burnie is a community bank with eight branch offices serving Anne Arundel County, MD ( www.thebankofglenburnie.com ).

Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder

Retrieved on: 
Mercoledì, Aprile 10, 2024
Liver injury, Safety, GLEN, Epistasis, ALT, Patient, European Journal, Liver, ALD, GGT, Annals of Internal Medicine, Aes, Manuscript, Internal medicine, Liver transplantation, Open access

According to the publication, low-dose AD04 did not significantly change biochemical markers of liver injury, such as ALT, AST, and Serum Bilirubin.

Key Points: 
  • According to the publication, low-dose AD04 did not significantly change biochemical markers of liver injury, such as ALT, AST, and Serum Bilirubin.
  • Additionally, while patients with AUD displayed elevated GGT levels, typically associated with increased alcohol consumption, this parameter remained unaffected by low-dose AD04.
  • This peer-reviewed publication emphasizes the safety and potential of AD04 in addressing the critical needs of individuals suffering from AUD and ALD.
  • Most importantly, the publication highlighted the potential of AD04 for the treatment for AUD among patients with a specified genetic background.

PickleRage Makes a Racket in Glen Burnie with New Indoor Pickleball Club Opening Soon

Retrieved on: 
Giovedì, Aprile 18, 2024
Relaxation, GLEN

GLEN BURNIE, Md., April 18, 2024 /PRNewswire/ -- PickleRage , a premier indoor pickleball club franchisor, announced its expansion into Maryland with the upcoming opening of a new corporate-operated club in Glen Burnie.

Key Points: 
  • GLEN BURNIE, Md., April 18, 2024 /PRNewswire/ -- PickleRage , a premier indoor pickleball club franchisor, announced its expansion into Maryland with the upcoming opening of a new corporate-operated club in Glen Burnie.
  • Designed to provide pickleball players with an unparalleled playing experience, PickleRage at Glen Burnie will boast 10 joint-friendly CushionX courts equipped with advanced video recording and livestreaming capabilities.
  • "We are thrilled to expand our presence into Glen Burnie and offer the community a premium indoor pickleball experience," said Chris Daiss, vp of real estate and construction.
  • PickleRage at Glen Burnie is committed to elevating the pickleball experience for players in the community.